Global pyrimethamine market is estimated to be valued at USD 1.21 Bn in 2024 and is expected to exhibit a CAGR of 5.5% during the forecast period (2024-2031). Pyrimethamine is an antifolate drug used for the treatment of protozoan infections such as malaria and toxoplasmosis. It works by inhibiting dihydrofolate reductase (DHFR), an enzyme involved in folate synthesis. This prevents protozoan parasites from producing essential folate and halts their growth. Pyrimethamine is often used in combination with other antimalarial drugs to enhance efficacy and reduce resistance development. Resistance to pyrimethamine has emerged due to mutations in the DHFR gene among Plasmodium species, complicating treatment strategies. Consequently, ongoing research focuses on developing new inhibitors targeting DHFR or related pathways to combat resistant strains effectively:

Market Dynamics:                                                                                                                              

The pyrimethamine market is driven by the growing prevalence of malaria in tropical and subtropical regions globally. As per the WHO, in December 2023, the estimated number of malaria deaths stood at 608,000 in 2022 compared to 610,000 in 2021. Increasing anti-malarial drug resistance is also boosting the demand for alternative treatment options like pyrimethamine. However, stringent regulatory approval processes for new drugs and the need for close medical supervision due to potential side effects can hamper market growth. The market also presents opportunities for combinations with other antimalarials to expand treatment applications and overcome resistance. Entry of newer generic manufacturers especially in developing countries can help improve the accessibility of pyrimethamine.

Key features of the study:

- This report provides in-depth analysis of the global pyrimethamine market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year

- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

- It profiles key players in the global pyrimethamine market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies

- Key companies covered as a part of this study include Dr. Reddy's Laboratories Ltd., Alvogen, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., AdvaCare Pharma, Swipha, Cerovene Inc., Vyera Pharmaceuticals

- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

- The global pyrimethamine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pyrimethamine market.

Market Segmentation

• By Dosage Form Insights (Revenue, USD Bn, 2019 - 2031)
• • Tablets
  • Capsules
• By Strength Insights (Revenue, USD Bn, 2019 - 2031)
• • 25 mg
  • 50 mg
  • 75 mg
  • Others
• By Indication Insights (Revenue, USD Bn, 2019 - 2031)
• • Malaria
  • Toxoplasmosis
  • Others
• By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
• • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
• • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
• • Reddy's Laboratories Ltd.
  • Alvogen
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • AdvaCare Pharma
  • Swipha
  • Cerovene Inc.
  • Vyera Pharmaceuticals